Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - AMS Laboratories Pty Ltd, SLHD RPA PET and Nuclear Medicine, Murray Goulburn Co LTD, Inova Pharmaceuticals Aus Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, efficacy, and safety of therapeutic goods in Australia, addressing the need for a robust framework to ensure that therapeutic goods available in the market meet specific health standards. This legislation was introduced to fill the gap left by the lack of a comprehensive regulatory system for therapeutic goods, ensuring that products such as medicines, medical devices, and blood products are safe for use by the public. The Act was enacted by the Commonwealth Parliament, reflecting a policy objective to protect and enhance public health by providing stringent controls over the manufacturing, supply, and advertising of therapeutic goods. The document published by the Department of Health Therapeutic Goods Administration on 21 January 2014, under the authority of Matthew Davis as the Delegate of the Secretary, lists the manufacturers granted licences to manufacture therapeutic goods. This publication is a direct application of Section 38 of the Therapeutic Goods Act, which mandates the public notification of such licences to maintain transparency and accountability in the therapeutic goods industry. The listed manufacturers, including AMS Laboratories Pty Limited, SLHD Royal Prince Alfred Hospital Department PET & Nuclear Medicine, Murray Goulburn Co-operative Co Ltd, and iNova Pharmaceuticals Australia Pty Ltd, are now authorised to manufacture therapeutic goods, subject to the ongoing compliance with the standards set forth by the Therapeutic Goods Administration.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities engaged in the manufacture, supply, and distribution of therapeutic goods within Australia. The Act grants licences to manufacturers ensuring that therapeutic goods meet quality, safety, and efficacy standards. The Act applies to a broad range of therapeutic goods including medicines, medical devices, blood and blood components, human tissue products, and complementary medicines. The geographical reach of the Act is national, as it applies across the Commonwealth of Australia, and is administered by the Therapeutic Goods Administration (TGA), a division of the Department of Health. The Act includes provisions for licensing requirements and standards that must be met by entities manufacturing therapeutic goods. The Act also provides for exclusions and exemptions under certain conditions, such as for research purposes or for certain low-risk goods. The scope of the Act is extended through subordinate legislation and regulations that further detail the requirements and processes for compliance. These regulations can specify additional criteria and conditions that manufacturers must adhere to, thereby ensuring the consistent application of the Act across different industries and entities.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) establishes the framework for regulating therapeutic goods in Australia. Section 38 of the Act provides the authority for the Secretary of the Department of Health to grant licences to manufacturers of therapeutic goods. This legislation mandates the publication of a list of manufacturers who have been granted such licences, as evidenced by the notice issued by Matthew Davis, Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration. This publication includes specific details of the licences granted to AMS Laboratories Pty Limited (Licence No. mi-2013-07582-1), SLHD Royal Prince Alfred Hospital Department PET & Nuclear Medicine (Licence No. mi-2012-LI-07749-1), Murray Goulburn Co-operative Co Ltd (Licence No. MI-2012-LI-11058-1), and iNova Pharmaceuticals Australia Pty Ltd (Licence No. MI-2012-LI-09136-1). The Act imposes several obligations and requirements on entities granted manufacturing licences. These include adhering to Good Manufacturing Practice (GMP) standards, ensuring the safety, quality, and efficacy of the therapeutic goods they produce. Licence holders must maintain records and documentation that demonstrate compliance with the Act and associated regulations. Additionally, they are required to notify the Therapeutic Goods Administration (TGA) of any significant changes to their manufacturing processes or facilities. Licence holders must also ensure that their products meet all labelling, packaging, and storage requirements outlined in the Act. Failure to comply with the requirements of the Therapeutic Goods Act 1989 may result in various offences, penalties, or civil and criminal consequences. Section 34HA of the Act provides that any person who manufactures a therapeutic good that does not comply with the standards set out in the Act commits an offence. The maximum penalty for this offence is significant, with fines reaching up to $2,200,000 for corporations and $440,000 for individuals. Additionally, individuals may face imprisonment for up to five years. Furthermore, the Act allows for the TGA to take enforcement actions, such as cancelling a licence, issuing infringement notices, or pursuing legal action against non-compliant entities. The enforcement measures are intended to ensure that therapeutic goods available in the Australian market meet the highest standards of safety and quality.